Nad+ — reference
A central redox coenzyme, administered by IV infusion or injection in wellness settings on claims of energy and cellular repair.
Regulatory status
Not FDA-Approved. Not FDA-approved for any of the uses it is marketed for. IV NAD+ is compounded and administered outside an approved indication.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of Minutes in plasma (rapidly metabolized); IV infusion protocols exist because of this. Not a stable circulating molecule — 'half-life' is a less meaningful concept here than for a typical peptide.
This figure is tagged Limited data in our evidence system. The available data does not support a confident single figure, so this entry is flagged accordingly. Read any curve built from it as illustrative only. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Nad+ FDA-approved?
What is the half-life of Nad+?
How reliable is that half-life figure?
What cautions are associated with Nad+?
Does Peptide Plug publish dosing for Nad+?
Does Peptide Plug sell Nad+?
Related tools
Free, no account required.
The public research page intentionally does not publish dosing. Pro subscribers can open the separate Protocol Library for structured indication, frequency, duration, notes, and review-first Cycle Builder import when a matching reference is available.
View Protocol Reference